GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, announced promising results from its Phase 2b clinical trial of GH001, an inhalable mebufotenin product candidate, for patients with treatment-resistant depression (TRD). The randomized, double-blind, placebo-controlled study demonstrated that GH001 achieved its primary endpoint, delivering an ultra-rapid antidepressant effect. Patients treated with GH001 experienced a significant […]